What to expect and when with the rollout of Eversense 365 implantable sensor.
Image courtesy of Ascensia Diabetes Care
CE mark for one-year CGM opens European rollout
In January 2026, Senseonics announced that Eversense 365 received CE mark approval in Europe, clearing the way for commercial launches in several EU countries. Initial markets expected to see the device include Germany, Italy, Spain and Sweden, with the approval expanding the company’s potential reach to more than 30 million people living with diabetes in the EU.
The Eversense 365 sensor is currently the longest-lasting CGM available, designed to remain implanted under the skin of the upper arm for up to 365 days. The sensor is inserted and removed by a healthcare professional, while a removable transmitter worn on the skin sends glucose readings to a smartphone app.
Unlike most CGMs which require a sensor change every 10–14 days, the one-year lifespan means users only need one insertion procedure per year.
Integration with automated insulin delivery systems
Another development reported in February 2026 involves integration between Eversense 365 and the Twiist automated insulin delivery system, developed by Sequel Med Tech.
The combined system links the implantable CGM with automated insulin dosing, creating a system designed to adjust insulin delivery using real-time glucose data.
Early reports indicate that the integrated system is already being used in real-world care settings in the United States for people with type 1 diabetes.
For Senseonics, partnerships like this are important as many people with type 1 diabetes now use hybrid-closed loop systems that combine CGMs and insulin pumps.
Financial outlook and company strategy
Senseonics has also outlined its financial expectations for the year ahead. The company projects global revenue of around $58–62 million in 2026, representing growth of roughly 65–76% year-on-year.
Part of this strategy involves bringing sales and marketing back in-house, following changes to its previous distribution arrangements with partners.
The company has previously suggested that longer-lasting sensors could help drive adoption after earlier versions of its implantable CGM had limited impact in the highly competitive CGM market dominated by patch-based sensors.
What this could mean for the UK
The UK market remains heavily dominated by short-wear CGMs such as Abbott’s FreeStyle Libre systems and Dexcom sensors, which are widely prescribed on the NHS.
Senseonics technology is different because:
• the sensor is implanted under the skin rather than inserted by the user
• the transmitter sits on the skin above the sensor and can be removed
• the sensor lasts months or up to one year, depending on the model
Earlier versions of the Eversense implantable CGM have been available in parts of Europe and the UK on a limited basis, although uptake has been much smaller than other CGMs.
The new one-year system and hybrid-closed loop compatibility may increase interest if the device becomes available more widely in Europe.
Looking ahead
Senseonics remains a small player in the global CGM market but is pursuing a distinct strategy focused on long-duration implantable sensors rather than short-wear disposable sensors.
Key developments to watch during 2026 include:
• the European launch ofEversense 365
• further integrations with insulin pumps and hybrid-closed loop systems
• potential expansion into additional markets beyond the first EU launch countries
If these plans succeed, the implantable CGM category could become a more visible alternative to traditional CGMs over the next few years!
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️Love My Libre.
Love My Libre is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our website whatcgm.comdoes not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.